|
|
K-562
|
|
|
HT Holden |
|
Biosafety Level: |
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension |
|
|
Homo sapiens (human)
|
|
|
lymphoblast
|
|
|
Organ: bone marrow Disease: chronic myelogenous leukemia (CML) |
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
transfection host (Nucleofection technology from Lonza) |
|
|
Yes
|
|
|
CD7 (25%) |
|
|
Amelogenin: X CSF1PO: 9,10 D13S317: 8 D16S539: 11,12 D5S818: 11,12 D7S820: 9,11 THO1: 9.3 TPOX: 8,9 vWA: 16 |
|
|
The stemline chromosome number is triploid with the 2S component occurring at 4.2%. Fifteen markers (M1 and M(15)) occurred in nearly all S metaphases. Spontaneous non-specific dicentrics occurred, but rarely. Unstable markers were also rarely seen. The X was disomic, and N9 was nullisomic. |
|
|
AK-1, 1 ES-D, 1 G6PD, B GLO-I, 2 Me-2, 0 PGM1, 0 PGM3, 1 |
|
|
53 years |
|
|
female |
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
|
|
Protocol: Cultures can be maintained by the addition or replacement of fresh medium. Start new cultures at 1 X 10 exp5 viable cells/ml. Subculture at 1 X 10 exp6 cells/ml. Medium Renewal: Every 2 to 3 days |
|
|
Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature |
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005 recommended serum:ATCC 30-2020 purified DNA:ATCC CCL-243D purified RNA:ATCC CCL-243R |
|
|
867: Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 56: 344-350, 1980. PubMed: 6996765 1101: Ortaldo JR, et al. Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J. Natl. Cancer Inst. 59: 77-82, 1977. PubMed: 69036 22609: Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321-334, 1975. PubMed: 163658 26059: Lozzio BB, Lozzio CB. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk. Res. 3: 363-370, 1979. PubMed: 95026 26060: Andersson LC, et al. K562--a human erythroleukemic cell line. Int. J. Cancer 23: 143-147, 1979. PubMed: 367973 26061: Lozzio BB, et al. A multipotential leukemia cell line (K-562) of human origin. Proc. Soc. Exp. Biol. Med. 166: 546-550, 1981. PubMed: 7194480 26063: Dimery IW, et al. Variation amongst K562 cell cultures. Exp. Hematol. 11: 601-610, 1983. PubMed: 6576909 32357: Chan YJ, et al. Two distinct upstream regulatory domains containing multicopy cellular transcription factor binding sites provide basal repression and inducible enhancer characteristics to the immediate-early IES (US3) promoter from human cytomegalovirus. J. Virol. 70: 5312-5328, 1996. PubMed: 8764042 32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128 32446: Gan W, Rhoads RE. Internal initiation of translation directed by the 5'-untranslated region of the mRNA for eIF4G, a factor involved in the picornavirus-induced switch from cap-dependent to internal initiation. J. Biol. Chem. 271: 623-626, 1996. PubMed: 8557663 32561: Tiffany HL, et al. Enhanced expression of the eosinophil-derived neurotoin ribonuclease (RNS2) gene requires interaction between the promoter and intron. J. Biol. Chem. 271: 12387-12393, 1996. PubMed: 8647842 32704: Chan YJ, et al. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus. J. Virol. 70: 8590-8605, 1996. PubMed: 8970984 33044: Nauseel WM, et al. Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase. J. Biol. Chem. 271: 9546-9549, 1996. PubMed: 8621627 33174: Grune T, et al. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J. Biol. Chem. 271: 15504-15509, 1996. PubMed: 8663134 48829: Jondal M, Pross H. Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. Int. J. Cancer 15: 596-605, 1975. PubMed: 806545 48830: West WH, et al. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J. Immunol. 118: 355-361, 1977. PubMed: 299761 48833: Pross HF, et al. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J. Clin. Immunol. 1: 51-63, 1981. PubMed: 7334070 61237: Chen TR. Modal karyotype of human leukemia cell line, K562 (ATCCCCL 243). Cancer Genet. Cytogenet. 17: 55-60, 1985. PubMed: 3857109 61327: Wu SQ, et al. Extensive amplification of bcr/abl fusion genes clustered on three marker chromosomes in human leukemic cell line K-56. Leukemia 9: 858-862, 1995. PubMed: 7769849 |
|
|